NCT05191862View on ClinicalTrials.gov

Bioequivalence Study of PMR Compared to Cilostazol IR Tablets in Healthy Volunteers

PHASE1TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 23, 2022

Primary Completion Date

May 4, 2022

Study Completion Date

May 7, 2022

Conditions
Intermittent Claudication
Interventions
DRUG

Cilostazol 100 mg

One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)

DRUG

PMR 135 mg

Two PMR 135 mg at 08:00, single oral dose (total daily dose of 270 mg)

Trial Locations (1)

65802

Bio-Kinetic Clinical Applications, LLC, Springfield

Sponsors
All Listed Sponsors
lead

Genovate Biotechnology Co., Ltd.,

INDUSTRY